ArticleCancers2026
Integrin αvβ6 Expression in Parathyroid Adenomas and Adjacent Non-Neoplastic Parathyroid Tissue: Immunohistochemical Rationale for Integrin αvβ6-Targeted PET Imaging.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate preoperative localization of hyperfunctioning parathyroid tissue is essential for focused parathyroid surgery; however, localization remains challenging in a subset of patients with small, ectopic, multiglandular, or conventionally occult lesions.
methodsIntegrin αvβ6 expression was assessed immunohistochemically in 56 surgically resected parathyroid adenomas. Adjacent morphologically non-neoplastic parathyroid tissue was available in 51 cases and served as a paired comparator. Only membranous staining was scored. Staining intensity was categorized as 0, 1+ (weak), 2+ (moderate), or 3+ (strong), and the percentage of cells at each intensity was recorded. A weighted integrin αvβ6 expression score was calculated as (1 ×% weak) + (2 ×% moderate) + (3 ×% strong), yielding a range of 0-300. Paired comparisons were performed, and correlations with adenoma dimensions were assessed.
resultsForty-five of 56 adenomas (80.4%) and 48 of 51 adjacent non-neoplastic samples (94.1%) met the predefined positivity criterion. The median integrin αvβ6-positive cell fraction and weighted score were 42.5% (interquartile range (IQR) 9.5-90.0%) and 60 (IQR, 10-140), respectively. The corresponding values in adjacent tissue were 50% (IQR, 20-80%) and 60 (IQR, 30-115), respectively. Neither the weighted score nor the total positive-cell fraction differed significantly in paired analyses (Wilcoxon
conclusionsIntegrin αvβ6 is a common membranous phenotype in both parathyroid adenomas and adjacent non-neoplastic parathyroid tissue and therefore should not be regarded as adenoma-specific. Nevertheless, adenomas more frequently contain strongly integrin αvβ6-positive cell populations, indicating a redistribution of expression intensity rather than a simple increase in overall positivity or weighted expression. These findings provide tissue-level support for integrin αvβ6-targeted parathyroid imaging and offer a plausible histopathological framework for the encouraging clinical performance of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.